SB239063

SB239063 is a potent p38MAPK inhibitor. SB 239063 had an IC(50) of 44 nM for inhibition of recombinant purified human p38alpha. In lipopolysaccharide-stimulated human peripheral blood monocytes, SB 239063 inhibited interleukin-1 and tumor necrosis factor-alpha production (IC(50) values = 0.12 and 0.35 microM, respectively). SB 239063 may be useful for the treatment of asthma and other inflammatory disorders.

Synonyms:

Tocris-1962;

Kinome_3168;

trans-1-(4-Hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridimidin-4-yl)imidazole;

4-[4-(4-fluorophenyl)-5-(2-methoxypyrimidin-4-yl)imidazol-1-yl]cyclohexan-1-ol

Properties:

Density: 1.35g/cm3

Boiling Point: 594.8ºC at 760 mmHg

Flash Point: 313.5ºC

Refractive Index: 1.655

Vapor Pressure: 5.42E-15mmHg at 25°C

p38 MAPK Inhibitors Related Products:

SB203580; Doramapimod; SB-202190; VX-702; PH-797804; Neflamapimod; TAK-715; SB239063; Losmapimod; Ralimetinib dimesylate

[1]. Bison S, et al. Effect of the p38 MAPK inhibitor SB-239063 on Lipopolysaccharide-induced psychomotor retardation and peripheral biomarker alterations in rats.Eur J Pharmacol. 2011 Jul 1;661(1-3):49-56. Epub 2011 Apr 27.

[2]. Ward KW, et al. SB-239063, a potent and selective inhibitor of p38 map kinase: preclinical pharmacokinetics and species-specific reversible isomerization.Pharm Res. 2001 Sep;18(9):1336-44.